FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3149488021> ?p ?o ?g. }

• W3149488021 endingPage "615" @default.
• W3149488021 startingPage "605" @default.
• W3149488021 abstract "About 5% of prostate cancer cases are metastatic at diagnoses. Radiotherapy of both primary tumor and secondary lesions can be, in addition to systemic treatments, a radical alternative for selected patients.Patients with de novo prostate carcinoma with bone or lymph node metastases were retrospectively reviewed. All patients received moderate hypofractionated IMRT/VMAT up to 63 Gy in 21 daily fractions of 3 Gy to prostate and metastases with neoadjuvant and concurrent androgen deprivation therapy (ADT). According to known advances some patients also received abiraterone, enzalutamide, or docetaxel.Between 2015-2020, we attended 26 prostate cancer patients (median age 69.5 years, range 52-84) with simultaneous oligometastases [mean 2.1 metastases, median 1.5 metastases (range 1-6)]. Eighteen patients (69%) presented lymph node metastases, 4 (15.5%) bone metastases and 4 (15.5%) both lymph node and bone metastases. With a median follow-up of 15.5 months (range 3-65 months), 16 patients (62%) are alive and tumor free while 10 (38%) are alive with tumor. Four patients (17%) developed tumor progression, out of irradiated area in all cases, with a median time to progression of 43.5 months (range 27-56 months). Actuarial progression-free survival (PFS) rates at 12 and 24 months were 94.1% and 84.7%, respectively. No grade > 2 acute or late complications were recorded.Simultaneous directed radical hypofractionated radiation therapy for prostate and metastases is feasible, well tolerated and achieves an acceptable PFS rate. However, further studies with longer follow-up are necessary to definitively address these observations." @default.
• W3149488021 created "2021-04-13" @default.
• W3149488021 creator A5008661548 @default.
• W3149488021 creator A5009855997 @default.
• W3149488021 creator A5010862068 @default.
• W3149488021 creator A5035259364 @default.
• W3149488021 creator A5036785129 @default.
• W3149488021 creator A5038070314 @default.
• W3149488021 creator A5046371829 @default.
• W3149488021 creator A5047374807 @default.
• W3149488021 creator A5047946760 @default.
• W3149488021 creator A5056339747 @default.
• W3149488021 creator A5066068652 @default.
• W3149488021 creator A5067938394 @default.
• W3149488021 creator A5068731038 @default.
• W3149488021 creator A5069603968 @default.
• W3149488021 creator A5077283459 @default.
• W3149488021 creator A5085924011 @default.
• W3149488021 date "2021-01-01" @default.
• W3149488021 modified "2023-10-11" @default.
• W3149488021 title "Radiation therapy with curative intention in men with de novo metastatic prostate carcinoma: shoot'em all!" @default.
• W3149488021 cites W2018856880 @default.
• W3149488021 cites W2025421597 @default.
• W3149488021 cites W2141944007 @default.
• W3149488021 cites W2152393981 @default.
• W3149488021 cites W2166339241 @default.
• W3149488021 cites W2176970460 @default.
• W3149488021 cites W2252704011 @default.
• W3149488021 cites W2296253991 @default.
• W3149488021 cites W2753460626 @default.
• W3149488021 cites W2775321189 @default.
• W3149488021 cites W2787804990 @default.
• W3149488021 cites W2802053856 @default.
• W3149488021 cites W2886626452 @default.
• W3149488021 cites W2889646458 @default.
• W3149488021 cites W2894350218 @default.
• W3149488021 cites W2895455649 @default.
• W3149488021 cites W2897236707 @default.
• W3149488021 cites W2906101844 @default.
• W3149488021 cites W2919810454 @default.
• W3149488021 cites W2955708664 @default.
• W3149488021 cites W3002890515 @default.
• W3149488021 cites W3013251573 @default.
• W3149488021 cites W3024645857 @default.
• W3149488021 cites W3037599956 @default.
• W3149488021 cites W3093087207 @default.
• W3149488021 doi "https://doi.org/10.5603/rpor.a2021.0077" @default.
• W3149488021 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8382082" @default.
• W3149488021 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34434577" @default.
• W3149488021 hasPublicationYear "2021" @default.
• W3149488021 type Work @default.
• W3149488021 sameAs 3149488021 @default.
• W3149488021 citedByCount "1" @default.
• W3149488021 crossrefType "journal-article" @default.
• W3149488021 hasAuthorship W3149488021A5008661548 @default.
• W3149488021 hasAuthorship W3149488021A5009855997 @default.
• W3149488021 hasAuthorship W3149488021A5010862068 @default.
• W3149488021 hasAuthorship W3149488021A5035259364 @default.
• W3149488021 hasAuthorship W3149488021A5036785129 @default.
• W3149488021 hasAuthorship W3149488021A5038070314 @default.
• W3149488021 hasAuthorship W3149488021A5046371829 @default.
• W3149488021 hasAuthorship W3149488021A5047374807 @default.
• W3149488021 hasAuthorship W3149488021A5047946760 @default.
• W3149488021 hasAuthorship W3149488021A5056339747 @default.
• W3149488021 hasAuthorship W3149488021A5066068652 @default.
• W3149488021 hasAuthorship W3149488021A5067938394 @default.
• W3149488021 hasAuthorship W3149488021A5068731038 @default.
• W3149488021 hasAuthorship W3149488021A5069603968 @default.
• W3149488021 hasAuthorship W3149488021A5077283459 @default.
• W3149488021 hasAuthorship W3149488021A5085924011 @default.
• W3149488021 hasConcept C121608353 @default.
• W3149488021 hasConcept C126322002 @default.
• W3149488021 hasConcept C126838900 @default.
• W3149488021 hasConcept C126894567 @default.
• W3149488021 hasConcept C143998085 @default.
• W3149488021 hasConcept C2776235491 @default.
• W3149488021 hasConcept C2777899217 @default.
• W3149488021 hasConcept C2779013556 @default.
• W3149488021 hasConcept C2780192828 @default.
• W3149488021 hasConcept C2780283643 @default.
• W3149488021 hasConcept C2780849966 @default.
• W3149488021 hasConcept C2781190966 @default.
• W3149488021 hasConcept C509974204 @default.
• W3149488021 hasConcept C71924100 @default.
• W3149488021 hasConceptScore W3149488021C121608353 @default.
• W3149488021 hasConceptScore W3149488021C126322002 @default.
• W3149488021 hasConceptScore W3149488021C126838900 @default.
• W3149488021 hasConceptScore W3149488021C126894567 @default.
• W3149488021 hasConceptScore W3149488021C143998085 @default.
• W3149488021 hasConceptScore W3149488021C2776235491 @default.
• W3149488021 hasConceptScore W3149488021C2777899217 @default.
• W3149488021 hasConceptScore W3149488021C2779013556 @default.
• W3149488021 hasConceptScore W3149488021C2780192828 @default.
• W3149488021 hasConceptScore W3149488021C2780283643 @default.
• W3149488021 hasConceptScore W3149488021C2780849966 @default.
• W3149488021 hasConceptScore W3149488021C2781190966 @default.
• W3149488021 hasConceptScore W3149488021C509974204 @default.
• W3149488021 hasConceptScore W3149488021C71924100 @default.

• next